Canaccord raised the firm’s price target on Olema Oncology to $22 from $16 and keeps a Buy rating on the shares. The firm thinks the past several updates and most recently the palbo combo update at ESMO Breast, have been completely in line with both preclinical data and mgmt messaging that the drug is stacking up to be best in class.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on OLMA:
- Olema Oncology breast cancer data a ‘home run,’ says H.C. Wainwright
- Olema Oncology: Median PFS was 4.6 months in Phase 2 palazestrant study
- Olema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant
- Olema Oncology appoints Garland to board of directors
- Olema Oncology Appoints Oncology Biotech Executive Scott Garland to Board of Directors
